Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB will pay up to $1.9 billion to acquire Zogenix, a U.S. biotech that markets the rare epilepsy treatment Fintepla, in a deal that adds to the Belgian…
Belgium's UCB said on Wednesday it had agreed to buy Zogenix in a deal worth up to $1.9 billion to gain the U.S. drugmaker's rare epilepsy drug Fintepla and…
UCB FY2025 results: FINTEPLA reached over 14,000 patients and families living with seizures associated with rare epileptic syndromes by end-2025, and is named…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
UCB acquired Zogenix for up to ~$1.9B ($26/share cash plus a $2/share contingent value right tied to EU approval of Fintepla in Lennox-Gastaut syndrome by 31 Dec 2023). The deal added Fintepla (fenfluramine), an FDA-approved oral solution for Dravet syndrome, expanding UCB's epilepsy and rare-neurology franchise as legacy antiseizure brands (e.g. Vimpat) faced generic erosion. The deal closed 7 March 2022. The acquisition thesis has since been validated: the FDA approved Fintepla for Lennox-Gastaut syndrome on 28 March 2022 and the EU followed on 8 February 2023 — satisfying the CVR milestone ahead of the deadline, so the full ~$1.9B consideration (including the $2/share CVR) was realized. Fintepla has scaled into a UCB growth driver, reaching over 14,000 patients with rare epileptic syndromes by end-2025.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Zogenix Inc. (this deal) | 2022 | $1.9B | — |
| UCB S.A. / Candid Therapeutics, Inc. | 2026 | $2.2B | — |
| UCB S.A. / Ra Pharmaceuticals, Inc. | 2019 | $2.1B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) | 2015 | $250M | 91 |
← Browse all deals · How we score deals
More: 2022 deals · UCB S.A. deals · Neurology deals